BRPI0512889A - uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia - Google Patents

uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia

Info

Publication number
BRPI0512889A
BRPI0512889A BRPI0512889-7A BRPI0512889A BRPI0512889A BR PI0512889 A BRPI0512889 A BR PI0512889A BR PI0512889 A BRPI0512889 A BR PI0512889A BR PI0512889 A BRPI0512889 A BR PI0512889A
Authority
BR
Brazil
Prior art keywords
antibody
leukemia
antigen binding
binding fragment
treating cancer
Prior art date
Application number
BRPI0512889-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Ruth Christine Matthews
Tracey Carter
James Peter Burnie
Original Assignee
Neutec Pharma Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0414885A external-priority patent/GB0414885D0/en
Priority claimed from GB0420845A external-priority patent/GB0420845D0/en
Priority claimed from GB0503566A external-priority patent/GB0503566D0/en
Application filed by Neutec Pharma Plc filed Critical Neutec Pharma Plc
Priority claimed from PCT/GB2005/002545 external-priority patent/WO2006003384A1/en
Publication of BRPI0512889A publication Critical patent/BRPI0512889A/pt

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
BRPI0512889-7A 2004-07-02 2005-06-30 uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia BRPI0512889A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0414885A GB0414885D0 (en) 2004-07-02 2004-07-02 Cancer therapy
GB0420845A GB0420845D0 (en) 2004-09-20 2004-09-20 Treatment of cancer
US61442304P 2004-09-30 2004-09-30
GB0503566A GB0503566D0 (en) 2005-02-21 2005-02-21 Treatment for cancer
US65445805P 2005-02-22 2005-02-22
PCT/GB2005/002545 WO2006003384A1 (en) 2004-07-02 2005-06-30 Treatment of cancer

Publications (1)

Publication Number Publication Date
BRPI0512889A true BRPI0512889A (pt) 2008-04-15

Family

ID=39124615

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512889-7A BRPI0512889A (pt) 2004-07-02 2005-06-30 uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia

Country Status (8)

Country Link
JP (1) JP2008504355A (es)
BR (1) BRPI0512889A (es)
EC (1) ECSP077219A (es)
IL (1) IL180460A (es)
MA (1) MA28701B1 (es)
MX (1) MX2007000263A (es)
NZ (1) NZ552508A (es)
SG (1) SG153877A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008305D0 (en) * 2000-04-06 2000-05-24 Neutec Pharma Plc Treatment of fungal infections

Also Published As

Publication number Publication date
MX2007000263A (es) 2007-07-20
IL180460A0 (en) 2007-06-03
ECSP077219A (es) 2007-03-29
NZ552508A (en) 2009-10-30
SG153877A1 (en) 2009-07-29
MA28701B1 (fr) 2007-06-01
JP2008504355A (ja) 2008-02-14
IL180460A (en) 2010-12-30

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
BR112019023754A2 (pt) anticorpo anti-sirpalpha ou um fragmento de ligação ao antígeno do mesmo, composição farmacêutica, e, combinação do anticorpo anti-sirpalpha ou da composição farmacêutica.
DK2269656T3 (da) Udvalgte antistoffer, som binder til aminophospholipider og deres anvendelse i behandling, så som cancer
IL184617A (en) Antibody against dr5 that includes mutations in the heavy and light chain of the full-length antibody 16e2 and various aspects related to this antibody
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
BRPI0622073A8 (pt) Uso de anticorpos pdgfralfa para fabricação de um medicamento para tratar um tumor ósseo
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
EA200800355A1 (ru) Нейтрализующие антитела человека против b7rp1
BRPI0410129B8 (pt) anticorpo anti-cs1 isolado, fragmento de ligação de antígeno, composto conjugado e composição farmacêutica
NO20070580L (no) Behandling av cancer.
AU4550801A (en) Herbal composition phy906 and its use in chemotheraphy
BR112022026236A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
BRPI0511187A (pt) método para tratar cáncer em um indivìduo
BR112021015036A2 (pt) Tratamento para câncer com imunoconjugados do anticorpo ror1
WO2006076525A3 (en) Combination cancer therapy with anti-psma antibodies
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
MX2009003039A (es) Utilizacion de un anticuerpo anti-cd151 para el tratamiento del cancer.
ECSP21044421A (es) Anticuerpos anti-pmel17 y conjugados de los mismos
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
BRPI0512889A (pt) uso de um anticorpo ou um fragmento de ligação de antìgeno deste e de pelo menos um agente anticáncer, preparação combinada, e, métodos de tratamento de cáncer, e de leucemia
AR055072A1 (es) Uso de anticuerpos anti- madcam para el tratamiento de enfermedad celiaca y esprue tropical
TR200302193T4 (tr) Kombinasyon kemoterapisi.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: ALTERADO DE: NEUTEC PHARMA PLC

B25G Requested change of headquarter approved

Owner name: NEUTEC PHARMA LTD. (GB)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080104513/RJ DE 30/07/2008.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013.